Edition:
United States

Bill Berkrot

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Jun 21 2017

Oscar Health files to expand insurance coverage in several states

Despite uncertainly over the future of U.S. healthcare that has prompted major health insurers to pull out of several markets, upstart provider Oscar Health on Wednesday said it has filed to sell health insurance to individuals through Obamacare exchanges in a total of six states in 2018.

Jun 15 2017

Adamis wins U.S. approval to sell EpiPen rival, shares soar

Adamis Pharmaceuticals Corp said on Thursday it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that it intends to be a lower cost rival to Mylan NV's widely used EpiPen, sending its shares up more than 50 percent.

Jun 15 2017

Adamis wins U.S. approval to sell EpiPen rival, shares soar

Adamis Pharmaceuticals Corp said on Thursday it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that it intends to be a lower cost rival to Mylan NV's widely used EpiPen, sending its shares up more than 50 percent.

Jun 14 2017

BioTime's Renevia succeeds in pivotal European facial wasting trial

BioTime Inc said on Wednesday its Renevia system succeeded in meeting the main goal of a pivotal European trial for facial wasting associated with treatment for HIV, putting it on track to file for European approval this year.

Jun 14 2017

BioTime's Renevia succeeds in pivotal European facial wasting trial

BioTime Inc said on Wednesday its Renevia system succeeded in meeting the main goal of a pivotal European trial for facial wasting associated with treatment for HIV, putting it on track to file for European approval this year.

Jun 12 2017

J&J diabetes drug shows heart benefit in large safety study

Johnson & Johnson's type 2 diabetes drug Invokana significantly reduced the risk of serious heart problems in patients with established heart disease or at elevated risk in a pair of large studies, according to data presented at a medical meeting on Monday.

Jun 05 2017

Pfizer drug delays lung cancer growth longer than Astra's Iressa: study

A targeted drug being developed by Pfizer Inc held advanced lung cancer in check longer than AstraZeneca's Iressa in newly diagnosed patients, but with a higher rate of side effects, according to data presented on Monday.

Jun 04 2017

AstraZeneca's Lynparza slows advanced breast cancer progression: study

Women with advanced breast cancer who carry specific genetic mutations experienced double the response rate and delayed disease progression when treated with AstraZeneca Plc's Lynparza compared with standard chemotherapy, according to data from a late-stage trial presented on Sunday.

Jun 03 2017

Loxo's targeted drug helps variety of advanced cancers in small study

Three quarters of patients with a wide variety of advanced cancers responded to a Loxo Oncology Inc therapy that targets a specific genetic defect, according to data from a small study presented on Saturday at the year's most important oncology meeting.

May 23 2017

FDA clears Merck's Keytruda based on cancer genetics, not location

Merck & Co's immunotherapy Keytruda on Tuesday became the first cancer drug ever approved by the U.S. Food and Drug Administration based on a patients' specific genetic traits, regardless of where in the body the disease originated.

More From Around the Web

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary